AGILENT Q4 EARNINGS BEAT ESTIMATES WITH STRONG DIAGNOSTICS PERFORMANCE | $A (+0,33%)

QUARTERLY PERFORMANCE

- $A Reports Q4 adjusted EPS of $1.46, surpassing $1.41 consensus estimate

- Total revenue reached $1.70 billion, exceeding $1.67 billion forecast

- Adjusted net income of $418 million topped expectations of $405.1 million

SEGMENT BREAKDOWN

- Life Sciences & Applied Markets

* Revenue: $833 million (vs. estimate $845.4 million)

* Segment showed slight underperformance against projections

- Diagnostics & Genomics

* Revenue: $442 million (vs. estimate $417.3 million)

* Demonstrated strong outperformance, exceeding expectations

- Agilent Crosslab

* Revenue: $426 million (vs. estimate $423.6 million)

* Maintained steady performance above estimates

FORWARD GUIDANCE

Fiscal Year 2024 Outlook:

- Revenue projected between $6.790-$6.870 billion

- Represents growth of:

* 4.3% to 5.5% (reported basis)

* 2.5% to 3.5% (core basis)

Q1 FY2024 Guidance:

- Revenue expected between $1.650-$1.680 billion

- Projects range from -0.5% to +1.3% (reported)

- Core growth range: -2.0% to -0.2%

MANAGEMENT PERSPECTIVE

CEO Padraig McDonnell noted continued market recovery and solid execution by the Agilent team in Q4, supporting the company's positive performance against estimates.